亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas

CD5型 医学 细胞因子释放综合征 内科学 抗原 不利影响 淋巴瘤 嵌合抗原受体 胃肠病学 免疫学 T细胞 肿瘤科 免疫系统
作者
LaQuisa Chimere Hill,Rayne Helen Rouce,Meng-Fen Wu,Tao Wang,Royce Ma,Huimin Zhang,Birju Mehta,Natalia Lapteva,Zhuyong Mei,Tyler S. Smith,Lina Yang,Madhuwanti Srinivasan,Phillip M. Burkhardt,Carlos A. Ramos,Premal Lulla,Martha Arredondo,Bambi Grilley,Helen Elisabeth Heslop,Malcolm K. Brenner,Maksim Mamonkin
出处
期刊:Blood [Elsevier BV]
卷期号:143 (13): 1231-1241 被引量:73
标识
DOI:10.1182/blood.2023022204
摘要

ABSTRACT: Despite newer targeted therapies, patients with primary refractory or relapsed (r/r) T-cell lymphoma have a poor prognosis. The development of chimeric antigen receptor (CAR) T-cell platforms to treat T-cell malignancies often requires additional gene modifications to overcome fratricide because of shared T-cell antigens on normal and malignant T cells. We developed a CD5-directed CAR that produces minimal fratricide by downmodulating CD5 protein levels in transduced T cells while retaining strong cytotoxicity against CD5+ malignant cells. In our first-in-human phase 1 study (NCT0308190), second-generation autologous CD5.CAR T cells were manufactured from patients with r/r T-cell malignancies. Here, we report safety and efficacy data from a cohort of patients with mature T-cell lymphoma (TCL). Among the 17 patients with TCL enrolled, CD5 CAR T cells were successfully manufactured for 13 out of 14 attempted lines (93%) and administered to 9 (69%) patients. The overall response rate (complete remission or partial response) was 44%, with complete responses observed in 2 patients. The most common grade 3 or higher adverse events were cytopenias. No grade 3 or higher cytokine release syndrome or neurologic events occurred. Two patients died during the immediate toxicity evaluation period due to rapidly progressive disease. These results demonstrated that CD5.CAR T cells are safe and can induce clinical responses in patients with r/r CD5-expressing TCLs without eliminating endogenous T cells or increasing infectious complications. More patients and longer follow-up are needed for validation. This trial was registered at www.clinicaltrials.gov as #NCT0308190.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
斯文败类的应助被DRJ采纳,获得10
3秒前
iman完成签到,获得积分10
14秒前
17秒前
Lucas的应助被科研通管家采纳,获得10
22秒前
null的应助被科研通管家采纳,获得10
23秒前
null的应助被科研通管家采纳,获得10
23秒前
Orange的应助被Culto采纳,获得10
24秒前
taku完成签到 ,获得积分0
26秒前
悦耳的翠绿完成签到,获得积分10
27秒前
迷人宛亦完成签到,获得积分10
27秒前
光亮豌豆完成签到,获得积分10
32秒前
无花果的应助被迷人宛亦采纳,获得10
32秒前
赘婿的应助被DRJ采纳,获得10
32秒前
lixuebin完成签到 ,获得积分10
39秒前
42秒前
Culto发布了新的文献求助10
48秒前
神勇友安完成签到,获得积分10
50秒前
50秒前
香蕉觅云的应助被cc采纳,获得10
51秒前
Akim的应助被萌yxy采纳,获得10
54秒前
59秒前
1分钟前
1分钟前
脑洞疼的应助被DRJ采纳,获得10
1分钟前
卤肉饭与石榴汁完成签到,获得积分10
1分钟前
华无剑的应助被今晚打老虎采纳,获得10
1分钟前
cc发布了新的文献求助10
1分钟前
萌yxy发布了新的文献求助10
1分钟前
传奇3的应助被甜甜的悲采纳,获得10
1分钟前
结实的寄柔完成签到,获得积分10
1分钟前
1分钟前
1分钟前
smithsmiles完成签到 ,获得积分20
1分钟前
1分钟前
迷人宛亦发布了新的文献求助10
1分钟前
共享精神的应助被DRJ采纳,获得10
1分钟前
顺利手链完成签到,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165968
求助须知:如何正确求助?哪些是违规求助? 9559396
关于积分的说明 21749984
捐赠科研通 7756746
什么是DOI,文献DOI怎么找? 3429092
关于科研通互助平台的介绍 2553386
邀请新用户注册赠送积分活动 2473667